Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents

Cancer is a significant global health challenge, comprising over 200 distinct types that severely impact life expectancy and account for high mortality rates in the 21st century. This complexity underscores the urgent need for ongoing research, preventive strategies, and improved treatment options....

Full description

Saved in:
Bibliographic Details
Main Authors: Rachida Mansouri, Abdeslem Bouzina, Yousra Ouafa Bouone
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Chemistry Proceedings
Subjects:
Online Access:https://www.mdpi.com/2673-4583/16/1/54
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849433050619838464
author Rachida Mansouri
Abdeslem Bouzina
Yousra Ouafa Bouone
author_facet Rachida Mansouri
Abdeslem Bouzina
Yousra Ouafa Bouone
author_sort Rachida Mansouri
collection DOAJ
description Cancer is a significant global health challenge, comprising over 200 distinct types that severely impact life expectancy and account for high mortality rates in the 21st century. This complexity underscores the urgent need for ongoing research, preventive strategies, and improved treatment options. In the quest for new anticancer drug candidates, arylnaphthalene lignan lactones—natural compounds found in plants like <i>Phyllanthus</i> and <i>Cleistanthus</i>—have gained attention due to their antioxidant, anti-inflammatory, and anticancer properties. An in silico study was conducted to evaluate their potential against colon cancer by targeting epidermal growth factor receptor (EGFR), a key tyrosine kinase. Docking simulations revealed that these compounds exhibited excellent stability within the active site of EGFR, with docking scores of −8.02 and −7.96 kcal/mol. Further, the derivatives demonstrated significant interactions, including hydrogen bonds with Met 769 and hydrophobic contacts within the EGFR cavity, akin to those formed by the known inhibitor 4-anilinoquinazoline. An ADMET analysis was also performed to evaluate their pharmacokinetic properties and toxicity, further supporting their potential as promising anticancer agents.
format Article
id doaj-art-c0eeeff9e3e34d63b8a8f13e0d800a51
institution Kabale University
issn 2673-4583
language English
publishDate 2024-11-01
publisher MDPI AG
record_format Article
series Chemistry Proceedings
spelling doaj-art-c0eeeff9e3e34d63b8a8f13e0d800a512025-08-20T03:27:13ZengMDPI AGChemistry Proceedings2673-45832024-11-011615410.3390/ecsoc-28-20218Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer AgentsRachida Mansouri0Abdeslem Bouzina1Yousra Ouafa Bouone2Environmental Research Center (CRE), Annaba 23000, AlgeriaLaboratory of Applied Organic Chemistry, Bioorganic Chemistry Group, Sciences Faculty, Chemistry Department, Badji Mokhtar-Annaba University, Box 12, Annaba 23000, AlgeriaLaboratory of Applied Organic Chemistry, Bioorganic Chemistry Group, Sciences Faculty, Chemistry Department, Badji Mokhtar-Annaba University, Box 12, Annaba 23000, AlgeriaCancer is a significant global health challenge, comprising over 200 distinct types that severely impact life expectancy and account for high mortality rates in the 21st century. This complexity underscores the urgent need for ongoing research, preventive strategies, and improved treatment options. In the quest for new anticancer drug candidates, arylnaphthalene lignan lactones—natural compounds found in plants like <i>Phyllanthus</i> and <i>Cleistanthus</i>—have gained attention due to their antioxidant, anti-inflammatory, and anticancer properties. An in silico study was conducted to evaluate their potential against colon cancer by targeting epidermal growth factor receptor (EGFR), a key tyrosine kinase. Docking simulations revealed that these compounds exhibited excellent stability within the active site of EGFR, with docking scores of −8.02 and −7.96 kcal/mol. Further, the derivatives demonstrated significant interactions, including hydrogen bonds with Met 769 and hydrophobic contacts within the EGFR cavity, akin to those formed by the known inhibitor 4-anilinoquinazoline. An ADMET analysis was also performed to evaluate their pharmacokinetic properties and toxicity, further supporting their potential as promising anticancer agents.https://www.mdpi.com/2673-4583/16/1/54arylnaphthalene lignan lactonescolon cancermolecular dockingtyrosine kinase
spellingShingle Rachida Mansouri
Abdeslem Bouzina
Yousra Ouafa Bouone
Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
Chemistry Proceedings
arylnaphthalene lignan lactones
colon cancer
molecular docking
tyrosine kinase
title Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
title_full Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
title_fullStr Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
title_full_unstemmed Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
title_short Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents
title_sort computational investigations of arylnaphthalene lignan lactones as anticancer agents
topic arylnaphthalene lignan lactones
colon cancer
molecular docking
tyrosine kinase
url https://www.mdpi.com/2673-4583/16/1/54
work_keys_str_mv AT rachidamansouri computationalinvestigationsofarylnaphthalenelignanlactonesasanticanceragents
AT abdeslembouzina computationalinvestigationsofarylnaphthalenelignanlactonesasanticanceragents
AT yousraouafabouone computationalinvestigationsofarylnaphthalenelignanlactonesasanticanceragents